Doubling Calcium and Phosphate in the Same TPN Bag

The hazard is calcium phosphate precipitation - dibasic calcium phosphate is poorly soluble and the solution can sit in a supersaturated state that looks clear until it does not.

It is not a simple threshold, and that is the judgment point. Whether precipitate forms depends on:

• Absolute concentrations of both calcium and phosphate, not just their ratio. Going from 1 g/10 mmol to 2 g/20 mmol roughly doubles each ion, and the risk rises more steeply than linearly.
• Amino acid concentration and pH - amino acids buffer the solution toward a lower pH, which increases calcium phosphate solubility. 5% amino acids gives less protection than a higher percentage.
• Phosphate species (potassium phosphate is a monobasic/dibasic mixture) and the calcium salt (gluconate vs. chloride).
• Order and point-of-mixing dilution - calcium and phosphate meeting as concentrates produces a locally high concentration even if the final bag is within limits.
• Temperature and time. Solubility changes with warming or cooling, and precipitate can appear hours after compounding, including after the bag leaves the pharmacy.
• Detectability. A 1.2 µm filter does not remove precipitate that forms after filtration, and small amounts are invisible.

So "the last bag was fine" is not evidence this one will be.

Sequence:

1. Add the phosphate to the bulk amino acid/dextrose volume first, with agitation, so it is diluted before any calcium is present - never inject calcium and phosphate into the same small volume or into a port where concentrates can meet.
2. Add the remaining electrolytes.
3. Add the calcium last, slowly, into the agitated diluted solution, and inspect the container against a black and white background at intervals during addition.

Before compounding, check the order against the pharmacy's validated calcium/phosphate compatibility limit for the amino acid percentage and final volume in use - not against a remembered rule of thumb.

If the order exceeds the limit, do not compound as written and do not "try it and look." Options to bring to the prescriber or covering clinician:

• Reduce phosphate or calcium, or split calcium into a separate infusion/container.
• Increase the amino acid concentration or final volume so the ion concentrations fall.
• Use a formulary solubilizing strategy (e.g., cysteine HCl) if one is validated at your site.

Document the attempted contact and the escalation. A 45-minute deadline is a workflow problem, not a reason to accept a physicochemical risk.

Clear at the end of compounding is necessary but not sufficient:

• Inspect immediately after compounding and again at final check against black and white backgrounds; the second look catches what the first glance missed.
• Recognize the supersaturated state. A clear bag at t = 0 does not exclude precipitation later, especially with temperature change in transport or at the bedside.
• Assign a conservative beyond-use date consistent with your stability data for this formulation and the demonstrated risk, rather than the maximum your policy allows.
• Require nursing to inspect before hanging and to use an in-line filter for administration, per the site's TPN policy.
• Document the compatibility check and the person who made it.

Hold the bag if any of the following: the order is above the validated limit, the calcium was added into an undiluted phosphate pool, the bag shows any haze/particulate at either inspection, the contact with the prescriber was never completed, or the compounder records show a line/sequence deviation. Escalate to the pharmacist-in-charge rather than releasing on the assumption that a clear appearance rules out risk.